Endotoxin Testing: How USP <85>, the New USP <86>, and Endotoxin Limits Determine Whether Injectables and Medical Devices Reach Market

Last Updated: May 7, 2026 — This article has been updated to reflect USP <86> (published 2025), the new compendial framework for non-animal recombinant Factor C (rFC) endotoxin testing; current endotoxin limits for injectables, water for injection, and medical devices; Monocyte Activation Test (MAT) applications for complex biologics; global pharmacopoeia requirements (EU Ph. Eur. 2.6.14, JP 4.01); and method suitability testing guidance.

⚡ Quick Take

• Endotoxin testing — detecting lipopolysaccharide (LPS) from Gram-negative bacteria — is mandatory under FDA, EMA, and PMDA regulations for all injectable drugs, IV fluids, and implantable devices before market release.
• USP <85> recognizes three LAL-based methods: Gel Clot, Turbidimetric, and Chromogenic. All require method suitability validation for each product matrix before routine use.
• USP <86>, approved July 2024 and published 2025, establishes the first dedicated framework for non-animal recombinant Factor C (rFC) and recombinant cascade reagent (rCR) testing.
• The maximum endotoxin exposure limit for most injectable drugs is 5 EU/kg body weight/hour; water for injection (WFI) must not exceed 0.25 EU/mL.
• The Monocyte Activation Test (MAT) detects both endotoxins and non-endotoxin pyrogens — critical for complex biologics and cell therapies where LAL testing alone is insufficient.

Why Does Endotoxin Testing Block Market Release for Injectables and Implantables?

Endotoxin testing determines whether a drug, biologic, or medical device carries lethal contamination from Gram-negative bacterial cell wall fragments — and without a passing result, no injectable, IV fluid, or implantable device legally ships to market under FDA, EMA, or PMDA jurisdiction. The test detects lipopolysaccharide (LPS), the toxic outer membrane component of Gram-negative bacteria that triggers fever, septic shock, and multi-organ failure in humans at concentrations as low as a few picograms per milliliter.

The United States Pharmacopeia Chapter <85> (Bacterial Endotoxins Test, BET) provides the globally referenced framework for this testing, mandated by 21 CFR 211.167(a) for all sterile and pyrogen-free drug products in the US. In July 2024, the USP Expert Committee voted to add Chapter <86> — the first dedicated chapter for non-animal recombinant Factor C (rFC) and recombinant cascade reagent (rCR) testing — published in 2025. Manufacturers, quality teams, and regulatory affairs professionals must now navigate both chapters. ContractLaboratory.com connects pharmaceutical and medical device companies with microbiology and pathogen detection laboratories and toxicology and biocompatibility testing specialists for GMP-compliant endotoxin testing. Related guides: biocompatibility testing for medical devices, sterility testing, and sterility assurance level (SAL).

Endotoxins: Heat-Stable Bacterial Toxins That Survive Standard Sterilization

Endotoxins are lipopolysaccharides (LPS) — large amphipathic molecules embedded in the outer membrane of Gram-negative bacteria, including Escherichia coli, Pseudomonas aeruginosa, Salmonella spp., and Klebsiella spp. Unlike proteinaceous toxins that can be inactivated by heat or chemical treatment, endotoxins are extraordinarily heat-stable — surviving standard steam sterilization cycles (121°C, 15 psi, 15 minutes) that kill the bacteria themselves. This thermal stability is the primary reason endotoxin testing cannot be replaced by sterilization validation alone.

When endotoxins enter the bloodstream — whether via injection, infusion, or implanted device — they activate the innate immune system through Toll-like receptor 4 (TLR4) signaling. This triggers a systemic inflammatory cascade that, at low concentrations, produces fever and rigors; at higher concentrations, it progresses to septic shock, disseminated intravascular coagulation (DIC), and multi-organ failure. The human immune system responds to endotoxin at concentrations below 0.1 nanogram per kilogram of body weight — a threshold that makes endotoxin one of the most potent human immune stimulants known. Standard autoclaving does not destroy endotoxins; depyrogenation (removal or inactivation) requires either dry heat (250°C for 30 minutes minimum), alkaline hydrolysis with sodium hydroxide, or acid treatment — conditions that cannot be applied to most finished pharmaceutical products or devices. This is why control of endotoxin occurs primarily through prevention (clean manufacturing environments, depyrogenated glassware and equipment, water for injection) and detection testing, not remediation.

For more information on contamination testing in pharmaceutical manufacturing, see the FDA’s Guidance for Industry on Pyrogen and Endotoxins Testing: Questions and Answers and USP Chapter <85> Bacterial Endotoxins Test.

What Are the Endotoxin Limits That Apply to Pharmaceuticals and Medical Devices?

USP <85> and FDA guidance establish product-specific endotoxin limits expressed in Endotoxin Units (EU) — a standardized unit of biological activity referenced to the USP Reference Standard Endotoxin (RSE). The endotoxin limit for a given product depends on its route of administration, dose, and contact with the human body. Manufacturers calculate their product-specific limit using the formula: Endotoxin Limit = K / M, where K is the threshold human exposure (EU/kg/hour for parenteral drugs), and M is the maximum dose administered per hour per kilogram of body weight.

• Injectable drugs and parenteral formulations: Maximum endotoxin exposure of 5 EU/kg body weight/hour for most parenteral drug products (USP <85> and FDA guidance). Intrathecal and intracisternal products (contact with cerebrospinal fluid) apply a much lower limit of 0.2 EU/kg/hour due to extreme CNS sensitivity to endotoxin.
• Water for Injection (WFI) and Sterile Water for Irrigation: Maximum 0.25 EU/mL (USP <85>). WFI endotoxin testing is one of the highest-volume routine endotoxin testing applications — daily or batch release testing in every GMP pharmaceutical manufacturing facility.
• Intravenous solutions and large-volume parenterals: Maximum 0.5 EU/mL (USP <85> general limit for IV solutions; product-specific limits in individual monographs may be lower).
• Medical devices (USP <161> — Transfusion and Infusion Assemblies): USP Chapter <161> and CDRH guidance establish endotoxin limits for devices expressed in EU/mL of device extract or EU/device, depending on contact type. Devices in contact with intravascular systems: 0.5 EU/mL of extract. Devices in contact with cerebrospinal fluid (e.g., ventricular shunts, intrathecal catheters): 0.06 EU/device. These limits require product-specific endotoxin extraction and testing protocols appropriate to the device’s geometry, materials, and intended contact area.
• Biological products and vaccines: Product-specific limits in individual biologics license applications (BLA), typically defined in the product specification sheet. Complex biologics may require Monocyte Activation Test (MAT) validation in addition to or instead of LAL — see below.

A critical practical point: the endotoxin limit is calculated for the product as administered, not per unit volume. A concentrated drug with a very small administered volume has a very low endotoxin limit per mL of product. Quality teams and contract laboratory partners must confirm whether the endotoxin limit provided by the sponsor is correctly derived from the clinical dose and route of administration before initiating method development.

USP <85> Endotoxin Testing Methods: Gel Clot, Turbidimetric, and Chromogenic Compared

USP <85> recognizes three Limulus Amebocyte Lysate (LAL)-based methods and accepts alternative methods (including rFC and MAT) with full validation. USP <86> (published 2025) provides the dedicated framework for rFC and recombinant cascade reagent (rCR) testing. The following comparison covers all five commercially available approaches:

Method	Chapter / Standard	Detection type	Format	Best application
Gel Clot LAL	USP <85>	Qualitative (pass/fail) or semi-quantitative	96-well tubes; visual endpoint	Simple product matrices with minimal interference; limit testing; pass/fail release; cost-effective for lower throughput
Turbidimetric LAL	USP <85>	Quantitative (kinetic or endpoint)	96-well microplate; spectrophotometer at 360-405 nm	High-volume pharmaceutical QC (batch release, WFI monitoring); automated plate-reader systems; good for turbid samples
Chromogenic LAL	USP <85>	Quantitative (kinetic or endpoint)	96-well microplate; spectrophotometer at 405 nm	Widest dynamic range; colored, opaque, or high-protein samples; regulatory submissions requiring high precision; most interference-resistant of three LAL methods
Recombinant Factor C (rFC)	USP <86> (2025); FDA accepts with USP <1225> validation	Quantitative (fluorometric endpoint)	Microplate; fluorometer; Lonza PyroGene; Charles River Accucyte; FUJIFILM Wako PyroStar Neo+	No horseshoe crab dependency; no beta-glucan false positives; equivalent sensitivity to chromogenic LAL; cell therapy/advanced therapy medicinal products (ATMPs); sustainability-driven manufacturing
Monocyte Activation Test (MAT)	EU Ph. Eur. 2.6.30 (compendial); USP <1225> validation required in US	Detects endotoxins AND non-endotoxin pyrogens (NEPs)	Human blood monocytes or cell line (e.g., THP-1); cytokine readout (IL-1β, IL-6, or TNF-α) by ELISA	Complex biologics; cell and gene therapy products; vaccines; situations where LAL cannot detect all pyrogenic activity; EU submissions where RPT replacement is required

The LAL Cascade: How Horseshoe Crab Biology Became Pharmaceutical Quality Control

All three USP <85> methods use Limulus Amebocyte Lysate (LAL) — a sterile, pyrogen-free aqueous extract prepared from the blood (hemolymph) of the American horseshoe crab (Limulus polyphemus) or Asian species (Tachypleus tridentatus). Horseshoe crabs lack an adaptive immune system; instead, their circulating amebocyte cells contain a clotting cascade that activates on contact with endotoxins — a defense mechanism evolved over 450 million years that pharmaceutical manufacturers now harness for quality control.

The LAL cascade proceeds through two primary pathways:

• Factor C pathway (endotoxin-specific): Endotoxin activates Factor C → activated Factor C activates Factor B → activated Factor B activates the clotting enzyme proclottin → clotting enzyme cleaves coagulogen to form a clot (gel) or activates a chromogenic or fluorescent substrate. This is the specific pathway the rFC assay replicates synthetically.
• Factor G pathway (beta-glucan-activated): (1,3)-β-D-glucans — fungal cell wall polysaccharides — activate Factor G in the LAL cascade, producing false-positive results in samples contaminated with or derived from fungal materials. This is the primary source of non-specific false positives in LAL testing. Solutions: use glucan-blocked LAL reagents (Factor G-inhibited); use rFC (which lacks the Factor G pathway entirely); or test with both a glucan-blocked and unblocked reagent and compare results.

The three LAL methods differ only in how the final endpoint is detected: Gel Clot reads physical clot formation; Turbidimetric reads the increase in turbidity as coagulogen polymerizes; Chromogenic reads the color released when the clotting enzyme cleaves a synthetic peptide-chromogen substrate.

The Horseshoe Crab Problem: Supply Chain Risk and Conservation Pressure Behind rFC Adoption

Producing LAL requires collecting and bleeding live horseshoe crabs at dedicated facilities. Each year, an estimated 500,000 or more horseshoe crabs are collected from Atlantic coastal populations, bled of approximately 30% of their blood volume, and returned to the ocean, with post-bleeding mortality estimates ranging from 10–30% depending on handling conditions. Horseshoe crab populations in some Atlantic regions have declined over recent decades, and the species is classified as vulnerable on the IUCN Red List.

The supply chain implications are significant: LAL is a natural biological product with inherent batch-to-batch variability (different crabs, ages, and collection locations produce lysates with different baseline reactivity); is subject to supply disruption from environmental events, regulatory restrictions, or population decline; and requires cold-chain storage and limited shelf life management. These concerns — both ethical and practical — are the primary drivers of investment in non-animal recombinant alternatives.

What Does USP <86> Mean for Manufacturers — and When Should rFC Testing Be Used?

In July 2024, the USP Expert Committee voted to approve new Chapter <86> — Bacterial Endotoxins Using Recombinant Reagents — for inclusion in the 2025 USP-NF publication. This is a landmark development: for the first time, USP provides a dedicated compendial framework (not just alternative method guidance) for non-animal-derived endotoxin detection reagents, specifically rFC and rCR (recombinant cascade reagent). Chapter <86> does not replace <85> — LAL-based testing continues unaffected — but it establishes a parallel, pharmacopoeially recognized pathway for recombinant testing.

Recombinant Factor C (rFC) is a genetically engineered version of the Factor C protein from the LAL cascade, produced in yeast (Saccharomyces cerevisiae) or insect cell expression systems without any horseshoe crab material. rFC reacts with LPS in the same specific way as native Factor C, but:

• Eliminates beta-glucan false positives: rFC has no Factor G component, so fungal beta-glucan contamination does not produce false positive results — a significant advantage for products derived from or processed in contact with fungal materials.
• Removes supply chain dependency: No horseshoe crab sourcing, no seasonal availability constraints, no inter-species or inter-harvest variability.
• Provides a fluorometric readout: Most commercial rFC assays (Lonza PyroGene; Charles River Accucyte; FUJIFILM Wako PyroStar Neo+) use a fluorescently tagged synthetic substrate — providing a quantitative result with sensitivity equivalent to chromogenic LAL (typically 0.001–10 EU/mL working range).
• Requires full method suitability validation: Per FDA guidance, rFC users must validate per USP <85> photometric quantitative method requirements and USP <1225> (Validation of Compendial Procedures). The FDA review division must be notified if switching from a previously accepted LAL method to rFC in an existing approved product’s testing program.

rFC testing is particularly appropriate for: cell therapy and advanced therapy medicinal products (ATMPs) where the biologic matrix creates LAL interference; manufacturers with strong sustainability commitments; products processed in fungal-derived bioreactors where beta-glucan contamination risk is elevated; and new product development where LAL has not yet been established in regulatory filings.

The Monocyte Activation Test (MAT): Detecting Pyrogens That LAL Cannot

The Monocyte Activation Test (MAT) detects all pyrogenic substances — including endotoxins and non-endotoxin pyrogens (NEPs) such as peptidoglycans (from Gram-positive bacteria), lipoteichoic acid, fungal glucans, and contaminating cytokines from cell culture. LAL, rFC, and rCR tests detect only endotoxins. Products that contain or are processed using biological matrices can carry NEP contamination that produces pyrogenic responses in humans but yields a negative LAL result — making LAL alone insufficient for complete pyrogen assessment.

The MAT exposes human peripheral blood mononuclear cells (PBMCs) or a standardized monocyte cell line (typically THP-1) to the test material, then measures the cytokine response — typically interleukin-1β (IL-1β), IL-6, or tumor necrosis factor-α (TNF-α) — by ELISA or multiplex immunoassay. The presence and magnitude of the cytokine response reflect the material’s pyrogenic potential across all pyrogen classes.

• European Pharmacopoeia (Ph. Eur.) 2.6.30: The MAT is a compendial method in the European Pharmacopoeia and is explicitly required to replace the Rabbit Pyrogen Test (RPT) for many product types. Ph. Eur. General Chapter 5.1.13 confirms that MAT must replace RPT for applicable products, with only product-specific verification required — not a full de novo validation.
• United States Pharmacopeia and FDA: The MAT lacks a dedicated USP chapter (as of 2025), so it is classified as an alternative method requiring full validation per USP <1225> to be accepted in US regulatory submissions. FDA review divisions consider MAT on a case-by-case basis — particularly for biologics license applications (BLA) where the sponsor can demonstrate that LAL alone does not adequately characterize pyrogenic risk.

MAT is the method of choice for: vaccines and viral vectors (which may contain NEPs from the production system); recombinant proteins with complex formulations; cell therapies and gene therapies; and any product where the Rabbit Pyrogen Test was historically required, and the sponsor is seeking to transition to an in vitro alternative. The European Medicines Agency provides guidance on MAT validation for biologics through its biological guidelines.

What Is Method Suitability Testing — and Why Does It Determine Whether Your Endotoxin Test Is Valid?

Method suitability testing (also called the Inhibition/Enhancement test) is a mandatory validation step under USP <85> that must be completed before any endotoxin test method can be used for product release. It confirms that the product matrix itself does not interfere with the LAL (or rFC or MAT) reaction — either by inhibiting the cascade (producing false negatives that could release contaminated product) or by enhancing it (producing false positives that could incorrectly reject clean product).

The suitability test works by spiking product samples with a known quantity of endotoxin (typically 2 × the limit concentration as Control Standard Endotoxin, CSE) and testing alongside an endotoxin-spiked buffer control. Recovery of the spike within 50–200% of the expected value confirms the test is valid for that product. Recovery outside this range signals interference, and the test must be adapted:

• Dilution: Diluting the sample below the interference threshold — the simplest solution, but constrained by the endotoxin limit. If the endotoxin limit per mL is very low, dilution may place the sample below the test’s sensitivity, making this approach impractical.
• pH adjustment: Many samples outside the pH 6–8 range inhibit the LAL cascade. Adjusting pH with sodium hydroxide or HCl (while verifying no endotoxin contamination from the adjusting agent) can restore reactivity.
• Filtration or dialysis: Removing high-molecular-weight interferents (large proteins, lipids) through ultrafiltration or dialysis can reduce matrix interference — but must not remove endotoxin from the sample in the process.
• Detergent treatment: Certain formulations (emulsions, liposomal products, lipid nanoparticles, PFAS-containing excipients) require detergent treatment to disrupt lipid particles that either interfere with or mask endotoxin detection. USP <85> allows validated detergent treatments.
• Method switching: If one LAL method is unsuitable (e.g., Gel Clot fails due to turbidity), switching to Chromogenic (which tolerates more turbid samples) or rFC (which eliminates beta-glucan interference) may resolve the interference without dilution constraints.

Method suitability must be re-established whenever the product formulation, container/closure system, or manufacturing process changes in a way that could alter the matrix composition. It must also be repeated when switching between different LAL lots or reagent suppliers, because reactivity specifications can vary between products.

Global Endotoxin Testing Standards: USP <85>, EU Ph. Eur. 2.6.14, and JP 4.01

Manufacturers seeking regulatory approval in multiple markets must satisfy endotoxin testing requirements under three principal pharmacopoeias, which are harmonized in their core LAL method requirements through the Pharmacopoeial Discussion Group (PDG), but differ in requirements for alternative methods:

• United States Pharmacopeia (USP) <85> / <86>: USP <85> is the LAL reference standard. USP <86> (2025) provides the non-animal rFC/rCR framework. FDA regulations (21 CFR 211.167(a)) mandate testing per USP <85> or validated alternative.
• European Pharmacopoeia (Ph. Eur.) 2.6.14 / 2.6.30: Ph. Eur. Chapter 2.6.14 governs bacterial endotoxins testing (harmonized with USP <85>). Chapter 2.6.30 governs the Monocyte Activation Test — a compendial method in the EU that is actively replacing the Rabbit Pyrogen Test. General Chapter 5.1.13 establishes a risk-based pyrogenicity assessment framework and mandates MAT as the successor to RPT for products within its scope.
• Japanese Pharmacopoeia (JP) 4.01: Harmonized with USP <85> and Ph. Eur. 2.6.14 through the PDG process. Gel Clot, Turbidimetric, and Chromogenic LAL methods are all recognized. Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) follows the same fundamental endotoxin testing approach as the FDA and EMA.

The ICH Q6A guideline (Specifications for New Drug Substances and Drug Products: Chemical Substances) addresses endotoxin testing as a recommended specification attribute for parenteral products. ICH Q2(R2) governs the validation of analytical procedures — the framework under which LAL method suitability and rFC validation studies are conducted for regulatory submissions to all ICH member markets.

Pharmaceutical, Biotech, and Medical Device Applications Requiring Endotoxin Testing

Endotoxin testing is legally mandated for all products administered parenterally, in contact with cerebrospinal fluid, or implanted in sterile tissues. Routine testing programs span the entire pharmaceutical and medical device manufacturing chain:

• Injectable pharmaceuticals (small molecules, biologics, generics): Every batch of parenteral drug product requires endotoxin testing prior to release. This includes small-molecule injectables (antibiotics, analgesics, cancer chemotherapy), monoclonal antibodies, fusion proteins, recombinant hormones, and biosimilars. Product-specific endotoxin limits apply from the approved product specification.
• Intravenous (IV) fluids and nutritional formulations: Saline, dextrose, total parenteral nutrition (TPN) solutions, and electrolyte formulations all require batch release endotoxin testing. These high-volume products drive significant endotoxin testing demand at contract testing laboratories.
• Vaccines: Complex formulations containing adjuvants, excipients, and biological components require both LAL and — increasingly — MAT testing to characterize total pyrogenic load. European regulators expect MAT validation for vaccine approval applications under Ph. Eur. 2.6.30.
• Cell and gene therapies (CGTs / ATMPs): Autologous and allogeneic cell therapy products, CAR-T cells, gene therapy vectors, and mRNA products may contain non-endotoxin pyrogens from the culture systems used in manufacturing. MAT testing (detecting all pyrogen classes) is increasingly required, and rFC may be preferred over LAL to eliminate beta-glucan false positives from the biological production environment.
• Medical devices: Any device intended for intravascular, intrathecal, urological, or surgically implanted use must meet device-specific endotoxin limits per USP <161> and FDA CDRH guidance. This includes catheters, stents, dialysis equipment, orthopedic implants, and drug-device combination products. See our guide to biocompatibility testing for medical devices for the full testing framework context.
• Water for Injection (WFI) and pharmaceutical process water: WFI — the critical high-purity water used in parenteral manufacturing — requires routine endotoxin monitoring at 0.25 EU/mL specification. Environmental monitoring programs in aseptic manufacturing facilities include endotoxin testing of water and process surfaces as part of the contamination control strategy.
• Biotechnology raw materials and excipients: Buffer components, cell culture media supplements, and excipients of biological origin that enter parenteral manufacturing streams are increasingly tested for endotoxin to prevent endotoxin introduction upstream of final product testing.

For pharmaceutical and biopharmaceutical product testing and medical device and healthcare product testing, ContractLaboratory.com connects manufacturers with qualified laboratories experienced in GMP endotoxin testing, method suitability validation, and regulatory filing support. See also our related resources on microbiology testing services and medical device sterilization validation.

GMP Requirements for Endotoxin Testing: Environment, Controls, and Analyst Qualification

Conducting a valid BET requires environmental controls that prevent endotoxin contamination of the test itself — which would produce false positives and potentially invalidate batch release decisions. Key GMP requirements include:

• Depyrogenated glassware: All glassware, sampling equipment, and containers must be depyrogenated by dry heat (≥250°C for ≥30 minutes, or equivalent validated cycle). Plastic disposable labware certified endotoxin-free is an alternative widely used in high-volume GMP testing environments.
• Endotoxin-free water (LAL Reagent Water, LRW): All dilutions, blanks, and standard preparation must use water certified to <0.005 EU/mL — the USP <85> requirement for LAL Reagent Water.
• Positive controls and Control Standard Endotoxin (CSE): Each test run must include a positive product control (PPC — product spiked with known endotoxin concentration), a standard curve (for quantitative methods), and blank controls. CSE (a commercially sourced endotoxin preparation calibrated against RSE) is used for routine testing; RSE (the USP primary standard) provides the calibration reference.
• Incubation temperature control: LAL reactions require precise temperature control at 37°C ± 1°C. Temperature deviations invalidate the test — either failing to activate the cascade (false negative below 36°C) or denaturing LAL reagents (above 38°C).
• Personnel training and SOPs: GMP regulations require documented training for all analysts performing BET. Standard Operating Procedures (SOPs) must cover LAL reagent handling, water preparation, product handling to prevent cross-contamination, calculation of endotoxin concentration and comparison to limit, out-of-specification investigation, and data recording.

How to Select a Contract Laboratory for Endotoxin Testing

Not all microbiology laboratories have the GMP infrastructure, validated methods, or regulatory submission experience required for endotoxin testing in pharmaceutical and device manufacturing contexts. Key qualifications to confirm when selecting a contract endotoxin testing laboratory:

• ISO/IEC 17025 accreditation covering the LAL or rFC method(s) required
• GMP compliance for batch release testing: 21 CFR Part 211 (US); EU GMP Annex 1 (EU)
• Experience with method suitability testing and interference resolution for your specific product matrix
• Regulatory submission support: ability to provide method validation documentation in CTD format for FDA, EMA, or PMDA submissions
• Availability of rFC testing (if beta-glucan interference is a known risk) or MAT (if NEP characterization is required for complex biologics)
• Turnaround time capability aligned with your batch release schedule

ContractLaboratory.com connects pharmaceutical and biopharmaceutical companies and medical device manufacturers with accredited GMP endotoxin testing laboratories. Submit a testing request or contact our team.

Frequently Asked Questions About Endotoxin Testing

Conclusion: Endotoxin Testing as a Market Access Determinant

Endotoxin testing sits at the intersection of patient safety, regulatory mandate, and supply chain risk. USP <85>’s three LAL methods remain the workhorse of pharmaceutical batch release; USP <86>’s new rFC and rCR framework (published 2025) opens a validated non-animal pathway that addresses both supply chain concerns and beta-glucan interference limitations; and the Monocyte Activation Test’s compendial status in the European Pharmacopoeia signals the direction of travel for complex biologics and advanced therapies. Understanding which method applies to your product — and ensuring that method suitability is established before batch release testing begins — is not a technical detail. It is the decision that determines whether your product can legally ship.

ContractLaboratory.com connects pharmaceutical and biopharmaceutical manufacturers and medical device companies with accredited endotoxin testing laboratories. Submit a testing request or contact our team.Us for more information.